Background: Atherosclerotic lesions are heavily infiltrated by macrophages. Neopterin can be used as a marker of the activity of macrophages. Serum neopterin levels were elevated in non-renal patients with atherosclerosis. The intima-media thickness (IMT) of the carotid arteries in hemodialysis patients was significantly higher than in control subjects. In this study, we measured serum neopterin levels in hemodialysis patients and evaluated a possible correlation between neopterin levels and carotid IMT. Patients and Methods: Thirty-seven hemodialysis patients (26 male/11 female, mean age 47 ± 15 years) and 12 healthy subjects (8 male/4 female, mean age 43 ± 10 years) were included in this study. Serum neopterin levels were measured by using a commercial ELISA kit. Carotid IMT of the subjects were measured by high-resolution B-mode ultrasonography. Results: Carotid IMT values were 1.04 ± 0.29 and 0.77 ± 0.25 mm in hemodialysis patients and healthy controls, respectively (p < 0.01). Serum neopterin levels were 110.9 ± 19.1 and 3.8 ± 2.3 ng/ml in hemodialysis patients and healthy controls, respectively (p < 0.01). Serum neopterin levels were 103.2 ± 21.3 ng/ml in hemodialysis patients with IMT <1 mm (n = 15), and 116.7 ± 15.4 ng/ml in hemodialysis patients with IMT ≧1 mm (n = 22) (p < 0.05). Moreover, there was a significant correlation between serum neopterin levels and carotid IMT (p < 0.05, r = 0.363). Conclusion: Our findings suggest that neopterin could be associated with the severity of carotid atherosclerosis in hemodialysis patients.

Keywords:
Neopterin, Atherosclerosis, Carotid intima-media thickness, High-resolution B-mode ultrasonography
1.
Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899–1911.
2.
Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, Shoji T, Tabata T, Inoue T, Morii H: High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995;48:820–826.
3.
Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick TH: Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med 2001;110:198–204.
4.
Benedetto FA, Mallamaci F, Tripepi G, Zoccali C: Prognostic value of ultrasonographic measurement of carotid intima-media thickness in dialysis patients. J Am Soc Nephrol 2001;12:2458–2464.
5.
Hojs R: Carotid intima-media thickness and plaques in hemodialysis patients. Artif Organs 2000;24:691–695.
6.
Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991;64:5–15.
7.
Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA: Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003;89:993–997.
8.
Napoli C, D’Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W: Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997;100:2680–2690.
9.
Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-γ. J Exp Med 1984;160:310–316.
10.
Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER: Neopterin as a marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 1989;27:81–141.
11.
Fuchs D, Weiss G, Wachter H: Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993;101:1–6.
12.
Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, Reibnegger G, Tilz GP, Gerstenbrand F, Wachter H: Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994;106:263–271.
13.
Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B: Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1999;83:515–518.
14.
Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, Krebs A, Esterbauer H: Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991;89:203–208.
15.
Godai K, Uemasu J, Kawasaki H: Clinical significance of serum and urinary neopterins in patients with chronic renal disease. Clin Nephrol 1991;36:141–146.
16.
Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H, Hosoya T: Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dial Transplant 2002;17:1032–1036.
17.
Kato A, Odamaki M, Takita T, Maruyama Y, Kumagai H, Hishida A: Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 2002;61:1143–1152.
18.
Hoffmann G, Wirleitner B, Fuchs D: Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003;52:313–321.
19.
Herpfer I, Greilberger J, Ledisnki G, Widner B, Fuchs D, Jurgens G: Neopterin and 7,8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or copper. Free Radic Res 2002;36:509–520.
20.
Stenvinkel P, Heimburger O, Jogestrand T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002;39:274–282.
21.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000;148:209–214.
22.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767–1772.
23.
Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A: Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 2003;64:1472–1479.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.